Skip to main content

The Future of FDA and Cannabis Regulation (now available for On-Demand CLE)

Regulation of cannabis by the federal government, specifically the Food & Drug Administration, was unthinkable less than a decade ago, but it will someday soon be a reality. The FDA is already aware of the non-approved uses of cannabis to treat conditions such as AIDS wasting, epilepsy, neuropathic pain, and several others. The agency has also approved one cannabis-derived drug product: Epidiolex (cannabidiol), used to treat seizures, and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone), all of which treat nausea due to chemotherapy. These approvals don’t signal a trend toward legalization of cannabis, but they do show that the FDA’s studies of cannabis are starting to bear some fruit.

The most recent official guidance from the FDA regarding cannabis regulation was published in January 2021. In this communication, the FDA reassured readers that they are aware of the public interest in using cannabis to develop treatments and consumer products. But the FDA is known for being cautious. The stakes for getting it wrong are high when measured in lives lost. To make matters more complicated, the public is divided on the benefits and dangers of cannabis. However, with other countries experimenting with or outright approving cannabis, the FDA is clearly feeling the pressure to move on the issue of cannabis regulation in the United States.

This CLE will discuss the FDA’s current stance and what needs to happen to move the needle on the FDA’s regulation of cannabis. The discussion will be led by a panel of three cannabis regulation experts. Amber Littlejohn will serve as moderator. Littlejohn is the executive director of the Minority Cannabis Business Association in Washington, D.C., and director of the U.S. Hemp Authority. Patrick Goggin and Garrett Graff will round out the panel. Goggin is a Senior Attorney with the Hoban Law Group specializing in assisting both large and small cannabis businesses. Graff is a partner is Moye White LLP and nationally recognized as a Cannabis Law Trailblazer by National Law Journal.

This program is a must for anyone in the professional cannabis business who is eagerly awaiting FDA regulation and all the changes that come with it.


The Future of FDA and Cannabis Regulation


Popular posts from this blog

The International Cannabis Bar Association Welcomes the 2023-2025 Board of Directors | #INCBA

Current INCBA Executive Committee The International Cannabis Bar Association ( INCBA ) is proud to announce the appointment of our esteemed Board of Directors for the 2023-2025 term. Comprised of seven exceptional individuals, this distinguished group brings a wealth of experience and expertise to INCBA. The newly appointed Board of Directors will join Jessica McElfresh, Zach Kobrin, Meital Manzuri Lauren Rudick, Andrea Steel, and Katy Young. Their collective knowledge and dedication will play a pivotal role in shaping the future of INCBA. We extend our warmest congratulations and gratitude to the following accomplished professionals: Richard Cheng Shay Gilmore Jason Horst Amber Littlejohn David Ruskin Shoran Williams Jana Weltzin Click here to view board member details. INCBA looks forward to their invaluable contributions as the organization strives to raise the standard of legal services available to the cannabis industry, advocate for the rights of lawyers representing cannabis

Law360 Article by Meital Manzuri and Alexis Lazzeri on California Cannabis & Hemp Regulatory Changes

  In a recent Law360 article , Meital Manzuri , the Board Secretary of the International Cannabis Bar Association (INCBA) , and INCBA Students Committee Chair, Alexis Lazzeri , delved into the changing landscape of California's hemp and CBD regulations. The article dissects the impact of new laws like AB 45 and AB 420 on hemp product manufacturers across the nation. Manufacturers aiming to sell their hemp products in California must now adhere to state-specific regulations in addition to federal requirements. The article also highlights updates to hemp testing procedures, effective January 1, 2024, making it mandatory for products to undergo testing at a DEA-registered laboratory. A practical case study is included, demonstrating compliance standards for a hypothetical company. For more insights on the authors, please explore Manzuri Law . To learn more about the International Cannabis Bar Association , visit: https://incba.org .

Jessica McElfresh, INCBA Member and Board of Director, interviewed regarding a new California law banning employers from marijuana screening.

Jessica McElfresh, INCBA Member who also holds a seat on our Board of Directors , was interviewed by 10News ABC in San Diego (KGTV) regarding a new California law banning employers from marijuana screening.  "This is a big step." Jessica McElfresh is a criminal defense attorney specializing in cannabis law. She says there's been a push for a law like this for years. "In 13 years I've gotten hundreds of calls from people who were denied a job even when they disclosed it up front it didn't make a difference that it was medical." Click here to read the full story and watch the interview on the KGTV website.

INCBA Europe Conference at CB Expo in Zurich 2022 – a great success!

  On the weekend of September 10th, INCBA hosted the first ever Conference for Cannabis Lawyers in Europe at the CB Expo. Over the course of two days, seventeen attorneys from Europe and the US presented seven sessions on the main legal issues facing the European cannabis market. Topics included the principle of free movement of hemp and cannabis products within the EU, the legal classification of CBD products as food or cosmetics, contractual aspects of importing cannabis products into the EU, the legal hurdles in the legalization of recreational cannabis, and much more. The active and participatory audience included both lawyers as well as interested entrepreneurs who could take away valuable insights for their businesses. In addition to the unparalleled education, there was plenty of networking to be found, including the social reception at Cannavigia sponsored by INCBA on the eve of the conference, at the after-party of the conference itself, or at the closing dinner with INCBA Lea

INCBA Hosts the Global Cannabis IP Symposium at McGill University, Montreal

The International Cannabis Bar Association (INCBA) hosted  its   inaugural Global Cannabis Intellectual Property Symposium in September 2023 in Montreal, Canada.  The Symposium  convened  cannabis IP  legal  thought leaders and delved into the nuts  and  bolts of IP,  e.g.,   patents, trademarks, licensing and  litigation/ disputes , drilling down into the illegality doctrine and other nuances that impact the inconsistent treatment of cannabis IP  by governmental agencies and courts . In addition, the summit hosted an informative in-house counsel panel, a session  that focused  on the  science of the  plant  ( for non-scientists ) , an illuminating presentation on international treaties, and an ed i fying  exposition on the unusual impact of federal illegality on professional responsibility.  A hybrid event, attendees  were   in   person  at McGill University  and  on Zoom ,  and the program included  speakers from Canada, Europe, Mexico, United Kingdom, United States, and elsewhere. T